• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study.

作者信息

Selvaraj Katina J, Stewart Thomas, Frew John W

机构信息

Department of Dermatology, Concord Repatriation General Hospital, Sydney, Australia.

Department of Dermatology, Liverpool Hospital, Sydney, Australia.

出版信息

JAAD Int. 2023 Feb 25;11:143-144. doi: 10.1016/j.jdin.2023.02.006. eCollection 2023 Jun.

DOI:10.1016/j.jdin.2023.02.006
PMID:37128264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10148145/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/10148145/a73378db4db3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/10148145/b14d7c673b53/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/10148145/a73378db4db3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/10148145/b14d7c673b53/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba82/10148145/a73378db4db3/gr2.jpg

相似文献

1
Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study.结节性痒疹患者对度普利尤单抗反应的维持：一项回顾性队列研究。
JAAD Int. 2023 Feb 25;11:143-144. doi: 10.1016/j.jdin.2023.02.006. eCollection 2023 Jun.
2
Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.结节性痒疹中使用度普利尤单抗：当前证据的系统评价及应答预测因素分析。
J Dermatolog Treat. 2022 May;33(3):1547-1553. doi: 10.1080/09546634.2020.1853024. Epub 2020 Dec 3.
3
Dupilumab for the treatment of prurigo nodularis: A systematic review.度普利尤单抗治疗结节性痒疹的系统评价。
Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. eCollection 2023.
4
Dupilumab for prurigo nodularis: Case series and review of the literature.度普利尤单抗治疗结节性痒疹：病例系列及文献综述
Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.
5
Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series.度普利尤单抗治疗难治性结节性痒疹的病例系列研究
Cureus. 2020 Jun 21;12(6):e8737. doi: 10.7759/cureus.8737.
6
Recalcitrant prurigo nodularis treated successfully with dupilumab.度普利尤单抗成功治疗顽固性结节性痒疹。
JAAD Case Rep. 2019 May 8;5(5):471-473. doi: 10.1016/j.jdcr.2019.03.016. eCollection 2019 May.
7
Efficacy of dupilumab in prurigo nodularis in elderly patient.度普利尤单抗治疗老年结节性痒疹患者的疗效。
Dermatol Ther. 2020 Jan;33(1):e13201. doi: 10.1111/dth.13201. Epub 2019 Dec 28.
8
Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab.使用度普利尤单抗同时治疗Samter三联征和结节性痒疹。
JAAD Case Rep. 2021 Oct 15;18:20-22. doi: 10.1016/j.jdcr.2021.10.005. eCollection 2021 Dec.
9
Post-Stroke Asymmetric Prurigo Nodularis Responding to Dupilumab Treatment: A Case Report.中风后不对称性结节性痒疹对度普利尤单抗治疗有反应：一例报告
Brain Sci. 2022 May 5;12(5):605. doi: 10.3390/brainsci12050605.
10
Dupilumab Treatment for Prurigo Nodularis and Pruritis.度普利尤单抗治疗结节性痒疹和瘙痒症。
J Drugs Dermatol. 2019 Sep 1;18(9):940-942.

引用本文的文献

1
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.结节性痒疹：发病机制与潜在治疗靶点。
Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.
2
Molecular mechanisms of pruritus in prurigo nodularis.结节性痒疹瘙痒的分子机制。
Front Immunol. 2023 Nov 23;14:1301817. doi: 10.3389/fimmu.2023.1301817. eCollection 2023.

本文引用的文献

1
Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.结节性痒疹的转录组学特征及对 nemolizumab 的治疗反应。
J Allergy Clin Immunol. 2022 Apr;149(4):1329-1339. doi: 10.1016/j.jaci.2021.10.004. Epub 2021 Nov 29.
2
Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.度普利尤单抗对特应性皮炎患者的顽固性痒疹显示出缓慢而稳定的疗效。
J Dermatol. 2021 May;48(5):638-644. doi: 10.1111/1346-8138.15843. Epub 2021 Mar 20.
3
Dupilumab as promising treatment for prurigo nodularis: current evidences.
度普利尤单抗治疗结节性痒疹的疗效观察：现状及进展
J Dermatolog Treat. 2022 May;33(3):1306-1311. doi: 10.1080/09546634.2021.1886232. Epub 2021 Feb 15.
4
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.尼莫利珠单抗治疗中重度结节性痒疹的试验。
N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316.